GLRX2 and Sjogren syndrome: In the field of stem cell therapy for Sjögren’s syndrome, hypoxic ADSC-derived exosomes attenuate skin damage caused by primary Sjögren’s syndrome through GLRX2 delivery and ferroptosis suppression (33).